Skip to content

Earnings yield at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
3.6%-1.9pp
Glaukos logo
GlaukosGKOS
-3%+1.7pp
AbbVie logo
AbbVieABBV
0.9%-0.2pp
Bausch + Lomb logo
Bausch + LombBLCO
-3.9%-1.2pp
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
-1.6%-0.7pp
Boston Scientific logo
Boston ScientificBSX
3.8%+2.5pp

Other financials

Income statement

See full
Revenue$19.7M+12.5%
Gross profit$17.0M+12.5%
Operating income-$12.4M+10.4%
Net income-$13.0M+8.3%
EPS (diluted)-$0.24+14.3%

Balance sheet

See full
Cash & equivalents$85.0M-21.9%
Total debt$40.9M+1.1%
Total equity$53.9M-30.6%
Total assets$109.7M-15.4%

Cash flow

See full
Operating cash flow-$7.0M+39.4%
CapEx$60.0K
Free cash flow-$7.1M+38.9%

Valuation

See full
Market cap$294.9M+35.0%
Enterprise value$250.83M+59.0%
P/S3.7×+0.8×

Profitability

See full
Gross margin86.2%+0.5pp
Operating margin-44.8%-10.2pp
Net margin-46.8%-9.6pp
FCF margin-31.9%+0.2pp

Returns & leverage

See full
Return on equity-56.6%+4.3pp
Debt / equity0.8×+0.2×
Current ratio5.9×-4.6×

Where this comes from

Calculated from Sight Sciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Sight Sciences, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sight Sciences, Inc.'s earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sight Sciences, Inc.'s earnings yield?
Sight Sciences, Inc. (SGHT) reported earnings yield of -18.3% in Q1 2026.
How has Sight Sciences, Inc.'s earnings yield changed year-over-year?
Sight Sciences, Inc.'s earnings yield increased by 54.4% year-over-year, from -40.1% to -18.3%.
What is the long-term trend for Sight Sciences, Inc.'s earnings yield?
Over 4 years (2021 to 2025), Sight Sciences, Inc.'s earnings yield has grown at a 5.0% compound annual growth rate (CAGR), from -7.5% to -9.2%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.